Clinical Trial Update: Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder [Phase 2]

View source ↗

Summary

The phase 2 trial evaluating eculizumab for acute attacks of neuromyelitis optica spectrum disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Status: WITHDRAWN